Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 58 Busan 23 Seongnam 19 Daegu 15 Incheon 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital183 Yonsei University143 Samsung Medical Center142 Merck Sharp & Dohme LLC111 Clear sponsor filter
Site location
Seoul58 Busan23 Seongnam19 Daegu15 Incheon15
All 42 locations
Target enrolment
to

Trials with a site in Seoul

58 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Eli Lilly and Company
Phase 3
150
Seongnam-si, Seoul
2026-09
Not yet open
Eli Lilly and Company
Phase 3
170
Bucheon-si, Deagu, Junggu, Seongnam, Seoul
2026-09
Recruiting
Eli Lilly and Company
Phase 3
1,000
Ansan-si, Gwangju, Jeju City, Seoul
2026-08-14
Recruiting
Eli Lilly and Company
Phase 2
606
Bupyeong-gu, Dongjak-gu, Gyeongsan-si, Seoul, Ulsan, Wŏnju
2026-08-07
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Seoul
2026-05-28
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Gangnam-gu, Incheon, Namdong-gu, Seoul
2026-05-20
Recruiting
Eli Lilly and Company
Phase 2
60
Dongjak-gu, Incheon, Jeonju, Seoul
2026-04-14
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Busan, Daegu, Daejeon, Gwangju, Gyeongsan-si, Pusan, Seoul, Wŏnju
2026-03-26
Recruiting
Eli Lilly and Company
Phase 3
800
Ansan-si, Seoul
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Ansan-si, Gwangju, Jeju City, Seoul
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Daegu, Dongjak-gu, Seoul, Uijeongbu-si
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
800
Cheonan-si, Deagu, Gangnam-gu, Gyeongsan-si, Incheon, Seoul
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
1,035
Ansan-si, Guri-si, Gwangju, Seongnam, Seoul
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
1,205
Daegu, Seoul
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,630
Daegu, Goyang-si, Seongnam, Seoul, Suwon
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Anyang-si, Bucheon-si, Busan, Gwangju, Junggu, Seoul
2025-09-30
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan
2025-09-02
Recruiting
Eli Lilly and Company
Phase 1/2
68
Busan, Seoul
2025-07-30
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Seoul
2025-07-28
Recruiting
Eli Lilly and Company
Phase 4
279
Seoul
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Seoul
2025-05-20
Recruiting
Eli Lilly and Company
Phase 3
125
Seongnam-si, Seoul
2024-11-18
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Ilsandong-gu, Seoul, Suwon
2024-09-19
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Seoul
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
510
Busan, Gyeonggi-do, Pusan, Seongnam-si, Seoul, Suwon
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Busan, Incheon, Seongnam-si, Seoul
2024-04-26
Active, closed
Eli Lilly and Company
Phase 3
301
Bupyeong-gu, Ansan-si, Seoul
2024-04-24
Recruiting
Eli Lilly and Company
Phase 3
90
Busan, Daegu, Seoul
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Recruiting
Eli Lilly and Company
Phase 3
1,264
Cheongju-si, Daegu, Deagu, Gangnam-gu, Goyang-si, Hwasun, Seoul, Suwon
2023-12-21
Active, closed
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Recruiting
Eli Lilly and Company
Phase 1
677
Seoul
2023-01-12
Active, closed
Eli Lilly and Company
Phase 3
15,374
Ansan-si, Busan, Seongnam, Seoul, Wŏnju
2022-10-11
Recruiting
Eli Lilly and Company
Phase 1
260
Seoul
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Seoul
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
368
Seongnam, Seoul, Daegu
2022-03-11
Active, closed
Eli Lilly and Company
Phase 3
152
Hwasun, Goyang-si, Seongnam, Busan, Seoul, Deagu
2021-12-20
Active, closed
Eli Lilly and Company
Phase 3
874
Cheonan-si, Namdong-gu, Suwon, Daegu, Busan, Seoul
2021-10-04
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Goyang-si, Suwon, Hwasun-gun, Seoul
2021-07-19
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Deagu, Seoul
2021-05-26
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
Seoul
2020-11-19
Active, closed
Eli Lilly and Company
Phase 1
200
Seoul
2020-10-01
Active, closed
Eli Lilly and Company
Phase 3
261
Goyang-si, Seongnam-si, Incheon, Seoul, Jinju, Dongjak-gu, Daejeon
2020-02-17
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Seoul
2019-12-10
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Seoul
2019-06-13
Active, closed
Eli Lilly and Company
Phase 2/3
393
Seoul, Songpagu
2018-11-26
Active, closed
Eli Lilly and Company
Phase 3
1,058
Busan, Daejeon, Gyeongsan-si, Haeundae-gu, Seoul, Wŏnju
2018-07-18
Active, closed
Eli Lilly and Company
Phase 1/2
857
Goyang-si, Seongnam, Seoul
2017-05-02
Active, closed
Eli Lilly and Company
Phase 2
309
Seoul
2016-05-19
Active, closed
Eli Lilly and Company
Phase 3
545
Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan
2015-05-06
Active, closed
Eli Lilly and Company
Phase 3
493
Incheon, Goyang-si, Seongnam, Seoul, Daegu, Ulsan
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
Goyang-si, Incheon, Seoul, Seowon-Gu, Suwon, Ulsan
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

33 of the 58 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 58 studies
PhaseStudiesRecruitingShare
Phase 3372063.8%
Phase 19615.5%
Phase 2548.6%
Phase 1/2416.9%
Phase 4223.4%
Phase 2/3101.7%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsorStudiesRecruiting
Eli Lilly and Company5833
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.